Effects of Cilostazol-Based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation: An Updated Meta-Analysis of the Randomized Controlled Trials
| Autor: | Wen Tian, Zhao-shuang Zhong, Liye Shi, Shijie Zhao, Guoxian Qi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Myocardial Infarction Hemorrhage 030204 cardiovascular system & hematology 030226 pharmacology & pharmacy law.invention 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Randomized controlled trial Restenosis law Internal medicine medicine Humans Pharmacology (medical) Myocardial infarction Adverse effect Randomized Controlled Trials as Topic business.industry Stent Drug-Eluting Stents General Medicine medicine.disease Cilostazol Treatment Outcome Drug-eluting stent Relative risk Cardiology Drug Therapy Combination business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Clinical Drug Investigation. 39:1-13 |
| ISSN: | 1179-1918 1173-2563 |
| DOI: | 10.1007/s40261-018-0711-8 |
| Popis: | The results of studies on cilostazol-based triple antiplatelet therapy (TAT) after drug-eluting stent (DES) implantation were inconsistent. To assess the effects of TAT compared with dual antiplatelet therapy (DAT) after DES/second-generation DES implantation, we performed a meta-analysis of randomized controlled trials (RCTs). All relevant studies evaluated were identified by searching the PubMed, EMBASE, Cochrane Library, and ISI Web of Science databases without time and language limitation. Subgroup analyses were performed to evaluate the efficacy and safety of TAT after second-generation DES implantation. Eleven RCTs involving a total of 4684 patients were included. The meta-analysis showed TAT was associated with significant beneficial effects on angiographic findings of in-stent restenosis [risk ratio (RR) 0.645, 95% confidence interval (CI) 0.470–0.885; P = 0.007], in-segment restenosis (RR 0.606, 95% CI 0.450–0.817; P = 0.001), in-stent late loss (RR – 0.095, 95% CI − 0.136 to − 0.054; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink